1. 台灣癌症防治網. HER2 陽性晚期乳癌病患治療的選擇. 癌症新探 2017; 82.
2. TCOG 乳癌研究委員會.乳癌診斷與治療共識. 臺北市，國家衛生研究院 (NHRI)癌症研究組&臺灣癌症臨床研究合作組織(TCOG); 2004.
3. Organization WH. GLOBOSCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. WHO. Published 2012. Accessed November 01, 2017.
4. 衛生福利部國民健康署. 中華民國 103 年癌症登記報告. 臺北市，衛生福利部 國民健康署, 2016. Accessed November 01, 2017.
5. 衛生福利部. 民國 105 年死亡統計年報. Accessed November 01, 2017.
https://dep.mohw.gov.tw/DOS/cp-3352-36826-113.html Published 2017. Accessed November 01, 2017.
6. 財團法人醫藥品查驗中心. 法洛德注射液 50 毫克/毫升(Faslodex) 醫療科技 評估報告. In 2016.
7. 張金堅. 晚期乳癌荷爾蒙治療的新曙光. 台灣醫界 2013; 56(3): 14-16.
8. 杜世興. 乳癌晚期復發轉移治療新選擇口服標靶 CDK4/6 抑制劑. 癌症預防 2017.
9. William J. Gradishar Mea. Breast Cancer, Version 1.2017 Featured Updates to the NCCN Guidelines. Published 2017. Accessed November 06, 2017.
10. Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology 2016; 34(25): 3069-3103.
11. Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology 2017; 28(1):
16-33.
12. Pfizer. 愛乳適 膠囊 75 毫克、100 毫克、125 毫克 Ibrance Capsules 75 mg、
100 mg、125 mg. In: Pfizer; 2016.
13. Polk A, Kolmos IL, Kumler I, Nielsen DL. Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence. ESMO open 2016; 1(6):
e000093.
14. Ehab M, Elbaz M. Profile of palbociclib in the treatment of metastatic breast cancer. Breast cancer (Dove Medical Press) 2016; 8: 83-91.
15. Methology WCCfDS. ATC/DDD Index. Published 2017. Accessed November.08, 2017.
16. 衛生福利部食品藥物管理署. 西藥、醫療器材、含藥化妝品許可證. Published 2017. Accessed November 08, 2017.
17. CADTH. pCODR EXPERT REVIEW COMMITTEE (pERC) INITIAL
RECOMMENDATION Palbociclib. In: CADTH-PCODR, ed.
https://www.cadth.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_abc_rec.
pdf; 2016. Accessed November 14, 2017
18. CADTH. Palbociclib (Ibrance) Resubmission ABC – pERC Final Recommendation. In: CADTH, ed.
https://www.cadth.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_a bc_fn_rec.pdf; 2016. Accessed November 14, 2017
19. PBAC. PALBOCICLIB, Capsule 75 mg, 100 mg and 125 mg, Ibrance® , Pfizer Australia Pty Ltd. In: PBAC, ed.
http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2017-03/files/
palbociclib-psd-march-2017.pdf; 2017. Accessed November 14, 2017
20. NICE. Palbociclib for treating hormone-receptor positive, HER2-negative breast cancer [ID915]. In: NICE.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10068; 2017. Accessed
November 14, 201721. SMC. Forthcoming Submission: palbociclib (Ibrance). In: SMC, ed.
https://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_Submissions/pa lbociclib_Ibrance; 2017. Accessed December 15, 2017
22. USFDA. FDA approves Ibrance for postmenopausal women with advanced breast cancer. Published 2015. Accessed November 16, 2017.
23. FDA U. Palbociclib (IBRANCE). Published 2017. Accessed. November 16, 2017 24. Chirila C, Mitra D, Colosia A, et al. Comparison of palbociclib in combination
with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Current medical research and opinion 2017;
33(8): 1457-1466.
25. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. The New England journal of medicine 2016; 375(20): 1925-1936.
26. Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast cancer research : BCR 2016; 18(1): 67.
27. Wilson FR, Varu A, Mitra D, Cameron C, Iyer S. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative
advanced/metastatic breast cancer. Breast cancer research and treatment 2017;
166(1): 167-177.
28. Verma S, Bartlett CH, Schnell P, et al. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative
Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). The oncologist 2016; 21(10): 1165-1175.
29. Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Annals of oncology :
official journal of the European Society for Medical Oncology 2016; 27(6):
1047-1054.
30. Raphael J, Helou J, Pritchard KI, Naimark DM. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. European journal of
cancer (Oxford, England : 1990) 2017; 85: 146-154.
31. Mamiya H, Tahara RK, Tolaney SM, Choudhry NK, Najafzadeh M.
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Annals of Oncology 2017; 28(8): 1825-1831.
32. Bhattacharya K, Yang Y. A Cost-Effectiveness Analysis of Palbociclib and other Aromatase Inhibitors for Treatment of Advanced Breast Cancer. Value in Health;
19(3): A150.
33. Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer
Res Treat 2016; 158(1): 51-57.
34. Matter-Walstra K, Schwenkglenks M, Dedes KJ. Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast Cancer Research and Treatment 2017; 163(3): 635-635.
35. Hettle R, Suri G, Mistry R, Chandiwana D, Lee A. PCN119 - Cost-Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for
Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced/Metastatic Breast Cancer from A UK National Health Service Perspective. Value in Health 2017; 20(9): A433.
36. Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and
Immunohistochemical Biomarkers. Journal of Cancer Epidemiology 2014; 2014:
11.
37. 衛生福利部中央健康保險署. 癌症費用排行-105 年各類癌症健保前 10 大醫療
支出統計（106.0823 新增）.
https://www.nhi.gov.tw/Content_List.aspx?n=AE8F3C1B6EC35217&topn=CDA
985A80C0DE710. Published 2017. Accessed November 20, 2017.
38. Parise CA, Caggiano V. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and
Immunohistochemical Biomarkers. Journal of Cancer Epidemiology 2014; 2014:
11.
附錄一、療效文獻搜尋策略
資料庫 查詢日期 搜尋條件 篇數
Pubmed 2017.11.16 #1 ("postmenopausal"[All Fields]) AND ("advanced "[MeSH Terms] OR ("advanced"[All Fields]) OR
"metastatic"[All Fields] AND ("breast cancer"[All Fields])AND
(("palbociclib"[Supplementary Concept]
OR " palbociclib "[All Fields]) AND plus[All Fields] AND ("letrozole"[MeSH Terms] OR ("letrozole"[All Fields])
14
#2 #1 AND (Randomized Controlled Trial[ptyp])
3
#3 #1 AND (systematic[sb])AND (meta-analysis)
2
#4 selected 2
Embase 2017.11.16 #1 postmenopausal AND advanced OR metastatic) AND ('breast'/exp OR breast) AND ('cancer'/exp OR cancer) AND ('palbociclib'/exp OR palbociclib) AND plus AND ('letrozole'/exp OR letrozole)
47
#2 #1 AND ('meta-analysis'/de OR 'randomized controlled trial'/de OR 'systematic review'/de)
9
#3 selected 2
Cochrane Library
2017.11.16 #1 postmenopausal AND advanced OR metastatic breast cancer AND palbociclib plus letrozole
3
#2 #1 AND technology assessment 1
#3 selected 0
CRD 2017.11.16 #1 postmenopausal AND advanced OR metastatic breast cancer AND palbociclib plus letrozole
0
#2 selected 0
附錄二、經濟評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篇數 篩選後篇數
PubMed 2017.11.07 #1 breast cancer
#2 Palbociclib
#3 (((cost-effectiveness analysis) OR cost-utility analysis) OR cost-benefit analysis) OR cost-minimization analysis
#1 AND #2 AND #3
7 3
EMBASE 2017.11.07 #1 breast cancer
#2 Palbociclib
#3 (((cost-effectiveness analysis) OR cost-utility analysis) OR cost-benefit analysis) OR cost-minimization analysis
#1 AND #2 AND #3
11 1
Cochrane Library
2017.11.07 “Palbociclib” in “Economic Evaluations”
0 0 CRD 2017.11.07 #1 breast cancer
#2 Palbociclib
#3 (((cost-effectiveness analysis) OR cost-utility analysis) OR cost-benefit analysis) OR cost-minimization analysis
#1 AND #2 AND #3
0 0